The 40mg-Copaxone patent lawsuit (as opposed to the IPR) includes all four of TEVA's Orange-Book patents on 40mg Copaxone that were listed at the time of MNTA's Pagagraph-IV filing. Since then, TEVA listed a fifth patent in the Orange Book, but TEVA did not follow the usual Hatch-Waxman procedure by suing MNTA for infringement of the fifth patent.
On the 2Q16 CC, Craig Wheeler said that TEVA's fifth patent is highly similar to the other four patents, and hence the Court will merge the fifth patent into the patent trial that starts on Sep 26.
So, the short answer is: By Feb 2017 (when the 30-month H-W stay expires), there will very likely be a clear decision from the Court on all of the relevant patents.
Market Data 
Markets 
AI
